IPHA Stock Forecast & Price Target

Innate Pharma is attractive because the Sobi deal removed a major financing overhang, adding a $75M upfront payment and, with the €30M private placement completed in August, extending cash runway through 1Q28 while supporting TELLOMAK-3 execution. Its outlook is strengthened by multiple near-term catalysts, especially PACIFIC-9 topline data in 2H26 and IPH4502 phase 1 data on Nov 18, alongside lacutamab’s differentiated phase 2 profile in Sézary syndrome with a 42.9% ORR and 25.6-month median duration of response. The company also has meaningful partnership-driven and recurring revenue potential from collaboration and licensing agreements, with management and the analyst model pointing to substantial upside from up to $825M in remaining PACIFIC-9 milestones and lacutamab’s expanded CTCL opportunity.

Innate Pharma is a clinical-stage biotech with value tied to a small set of long-dated, high-risk assets, making the investment case highly dependent on successful clinical execution and eventual commercialization rather than current operating strength. Its valuation is built on risk-adjusted net present value of projected revenues through 2032 at an 11% discount rate and 0% terminal growth, with €798M attributed to lacutamab and monalizumab and only €83.5M in net pro forma cash, underscoring a narrow margin of safety. The outlook is negative because the business faces meaningful clinical, commercial, partnership, financial, and legal/intellectual property risks while revenue remains mainly reliant on collaboration and licensing agreements plus government research support.